We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-12.94%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
-$7.47M
Cap. Flow
+$285M
Cap. Flow %
20.99%
Top 10 Hldgs %
65.02%
Holding
35
New
4
Increased
13
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$72.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$71.5M
3
SRRK icon
Scholar Rock
SRRK
+$30.6M
4
MRUS
Merus
MRUS
+$26.1M
5
SLDB icon
Solid Biosciences
SLDB
+$24.9M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$18.3M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.8M
3
ALKS icon
Alkermes
ALKS
+$11.4M
4
ABVX
Abivax
ABVX
+$9.4M
5
BBOT
BridgeBio Oncology
BBOT
+$5.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$188M 13.87%
4,472,840
+598,658
+15% +$26.1M
NUVL
2
DELISTED
Nuvalent
NUVL
$132M 9.69%
1,855,000
+233,400
+14% +$18.2M
ELVN icon
3
Enliven Therapeutics
ELVN
$3.78B
$92M 6.78%
4,675,000
+470,000
+11% +$10.1M
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$82.2M 6.05%
1,150,000
-375,000
-25% -$18.3M
XENE icon
5
Xenon Pharmaceuticals
XENE
$6.32B
$78M 5.75%
2,325,000
-415,000
-15% -$15.8M
ALKS icon
6
Alkermes
ALKS
$8.82B
$64.4M 4.74%
1,950,000
-350,000
-15% -$11.4M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.16B
$64M 4.72%
+2,185,000
New +$72.5M
PCVX icon
8
Vaxcyte
PCVX
$7.89B
$62.3M 4.59%
1,650,000
+25,000
+2% +$2M
VERA icon
9
Vera Therapeutics
VERA
$2.54B
$61.5M 4.53%
2,561,782
+603,182
+31% +$19.4M
CLDX icon
10
Celldex Therapeutics
CLDX
$2.77B
$58.1M 4.28%
+3,200,000
New +$71.5M
SRRK icon
11
Scholar Rock
SRRK
$5.71B
$56.1M 4.13%
1,745,000
+795,000
+84% +$30.6M
COGT icon
12
Cogent Biosciences
COGT
$6.79B
$53.3M 3.93%
8,892,816
+2,011,187
+29% +$15.8M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.13B
$48.5M 3.58%
3,600,000
+1,200,000
+50% +$20.4M
NRIX icon
14
Nurix Therapeutics
NRIX
$2.43B
$47.3M 3.48%
3,978,907
+978,907
+33% +$16.4M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$34M 2.51%
2,367,578
+149,153
+7% +$2.44M
SYRE icon
16
Spyre Therapeutics
SYRE
$8.87B
$32.1M 2.36%
1,988,084
– –
PHVS icon
17
Pharvaris
PHVS
$2.39B
$30M 2.21%
1,911,433
– –
DFTX
18
Definium Therapeutics
DFTX
$5.73B
$26.5M 1.95%
4,525,000
+216,575
+5% +$1.55M
SLDB icon
19
Solid Biosciences
SLDB
$771M
$21.6M 1.59%
+5,825,000
New +$24.9M
DRUG
20
Bright Minds Biosciences
DRUG
$700M
$18M 1.33%
500,000
– –
CRDF icon
21
Cardiff Oncology
CRDF
$64.3M
$16.9M 1.25%
5,384,616
– –
ORKA
22
Oruka Therapeutics
ORKA
$5.56B
$14.6M 1.07%
1,419,714
– –
IKT icon
23
Inhibikase Therapeutics
IKT
$366M
$11.7M 0.86%
5,344,432
-580,568
-10% -$1.46M
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.25B
$11.2M 0.82%
2,000,000
– –
APGE icon
25
Apogee Therapeutics
APGE
$10.2B
$10.8M 0.8%
290,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Commodore Capital held 35 positions worth $1.36B, down 0.55% from $1.36B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Commodore Capital deployed $285M of net new capital in Q1 2025, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Agios Pharmaceuticals: 2,185,000 shares worth $64M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Soleno Therapeutics, an estimated $18.3M trimmed.

  • Commodore Capital's largest Q1 2025 buy was Agios Pharmaceuticals: 2,185,000 shares worth $64M.
  • Commodore Capital added most to Scholar Rock in Q1 2025, an estimated $30.6M increase.
  • Commodore Capital's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $18.3M.
  • Commodore Capital fully exited Abivax in Q1 2025, selling an estimated $9.4M.
  • Commodore Capital's ten largest holdings make up 65% of its $1.36B portfolio in Q1 2025.
  • Commodore Capital opened 4 new positions and closed 4 in Q1 2025.
  • Commodore Capital's portfolio value fell 0.55% quarter-over-quarter to $1.36B.

Based on Commodore Capital's 13F filing for Q1 2025, filed 15 May 2025.